Welcome to our dedicated page for Lifevantage news (Ticker: LFVN), a resource for investors and traders seeking the latest updates and insights on Lifevantage stock.
LifeVantage Corp (LFVN) delivers science-driven health solutions through nutrigenomic research and dietary supplements. This news hub provides investors and stakeholders with essential updates on corporate developments, product innovations, and market positioning in the nutraceutical industry.
Access timely regulatory filings, earnings reports, and press releases alongside analysis of scientific advancements. Our curated collection includes updates on weight management systems, cognitive enhancement products, and dermatological solutions backed by gene expression research.
Key content categories cover financial performance metrics, research partnerships, product launch details, and corporate governance updates. Bookmark this page for streamlined access to verified information supporting informed decisions about LFVN's market activities.
LifeVantage (Nasdaq:LFVN) declared a quarterly cash dividend of $0.04 per share, reflecting a 14.3% increase from the previous quarter. The dividend will be paid on June 14, 2024, to stockholders of record as of May 31, 2024.
LifeVantage reported financial results for the third quarter of Fiscal 2024 with revenue of $48.2 million, a 10.2% decrease from the prior year. Adjusted EBITDA increased by 54.7% to $5.1 million. Despite revenue declines in the Americas and Asia/Pacific & Europe, positive trends were seen in operating margins and productivity gains. The company repurchased shares and announced a cash dividend of $0.04 per share. Fiscal Year 2024 guidance projects revenue of $202-$205 million and adjusted EBITDA of $16-$18 million.
FAQ
What is the current stock price of Lifevantage (LFVN)?
What is the market cap of Lifevantage (LFVN)?
